3SBio Inc. (HKG:1530)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
23.30
-0.10 (-0.43%)
Jun 13, 2025, 4:08 PM HKT
277.63%
Market Cap 54.97B
Revenue (ttm) 9.69B
Net Income (ttm) 2.22B
Shares Out 2.36B
EPS (ttm) 0.90
PE Ratio 25.76
Forward PE 21.58
Dividend 0.25 (1.07%)
Ex-Dividend Date Jul 21, 2025
Volume 53,029,016
Average Volume 75,254,745
Open 23.40
Previous Close 23.40
Day's Range 22.55 - 24.20
52-Week Range 5.47 - 24.95
Beta 0.76
RSI 71.18
Earnings Date Aug 22, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5,577
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1530
Full Company Profile

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY Financial Statements

News

Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma

The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega deal for righ...

17 days ago - Benzinga

Pfizer Thinks Bigger With 3SBio Deal

26 days ago - Seeking Alpha

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

26 days ago - Investopedia

Pfizer strikes deal with China's 3SBio to license cancer drug

CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.

26 days ago - CNBC

Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal

Pfizer Inc. (NYSE: PFE) announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc. ‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion. The agree...

26 days ago - Benzinga